Procardia--Is Europe Ready for Group Purchasing?
Executive SummaryProCardia GMBH is trying to capitalize on the larger problem raised by the heart valve scandal: the prices hospitals and insurers pay for medical devices and equipment are becoming unaffordable in the highly cost-constrained German System. The company is now trying to build off its success in supplying lower-cost heart valves to create Europe's first true hospital purchasing group.
You may also be interested in...
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”